The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis
出版年份 2023 全文链接
标题
The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis
作者
关键词
-
出版物
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-11-03
DOI
10.1007/s00280-023-04609-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition
- (2021) Arshdeep Singh et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas
- (2021) Kennosuke Karube et al. Expert Review of Hematology
- The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
- (2021) S. Horwitz et al. ANNALS OF ONCOLOGY
- Vorinostat and fenretinide synergize in preclinical models of T-cell lymphoid malignancies
- (2020) Monish Ram Makena et al. ANTI-CANCER DRUGS
- Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase‑dependent manner
- (2019) Xiang‑Gui Yuan et al. Oncology Letters
- Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas
- (2018) Michelle A. Fanale et al. BLOOD
- Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway
- (2018) Jianan Zhou et al. INVESTIGATIONAL NEW DRUGS
- Zinc binding groups for histone deacetylase inhibitors
- (2018) Lei Zhang et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E
- (2018) Yichen Wang et al. Frontiers in Immunology
- Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
- (2018) Steven Horwitz et al. LANCET
- Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
- (2017) H Miles Prince et al. LANCET
- Low-dose decitabine enhances chidamide-induced apoptosis in adult acute lymphoblast leukemia, especially for p16-deleted patients through DNA damage
- (2017) Pengcheng Shi et al. PHARMACOGENOMICS
- Analysis of CTCL cell lines reveals important differences between mycosis fungoides/Sézary syndrome vs. HTLV-1+ leukemic cell lines
- (2017) Elena Netchiporouk et al. Oncotarget
- A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes
- (2016) Zhaoyun Liu et al. BIOMEDICINE & PHARMACOTHERAPY
- Cdc45 is limiting for replication initiation in humans
- (2016) Carsten Köhler et al. CELL CYCLE
- ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization
- (2016) Guangchuang Yu et al. Molecular BioSystems
- Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) F. d'Amore et al. ANNALS OF ONCOLOGY
- Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma
- (2015) S. Jain et al. CLINICAL CANCER RESEARCH
- Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma
- (2015) Madeleine Duvic DERMATOLOGIC CLINICS
- Advance and stagnation in the treatment of patients with lymphoma and myeloma: Analysis using population-based cancer registry data in Japan from 1993 to 2006
- (2015) Dai Chihara et al. INTERNATIONAL JOURNAL OF CANCER
- The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo
- (2015) Min-Wu Chao et al. Journal of Hematology & Oncology
- CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin
- (2015) R. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
- (2014) S. M. Horwitz et al. BLOOD
- Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas: Results of a Phase I Study
- (2014) Michelle A. Fanale et al. JOURNAL OF CLINICAL ONCOLOGY
- CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells
- (2012) Ke Gong et al. BIOCHEMICAL JOURNAL
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
- (2012) Barbara Pro et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
- (2011) R. L. Piekarz et al. BLOOD
- Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity
- (2011) Zhi-Qiang Ning et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study
- (2011) Owen A. O'Connor et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started